Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review).

ABSTRACT: Asthma is a variable chronic respiratory disease characterized by airway inflammation and hyperresponsiveness, bronchoconstriction, and mucus hypersecretion. While most patients with asthma achieve good control of the disease, 5-10% experience severe symptoms and recurrent exacerbation despite the maximal offered therapy with inhaled corticosteroids and long acting bronchodilators. In previous years, novel biological therapies have become available, and various asthma phenotypes that are characterized by specific biomarkers have been identified. Currently approved biological agents target inflammatory molecules of the type 2 inflammatory pathway, and are effective at decreasing the frequency of asthma attacks, controlling symptoms and decreasing use of systemic steroids. The present study

SUBMITTER: Fildan AP 

PROVIDER: S-EPMC8453334 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature